Condition: Non-Hodgkin Lymphoma · Hodgkin Disease Lymphoma · Non-Hodgkin Lymphoma Refractory/ Relapsed · Sponsor: Seda S. Tolu
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
This description comes directly from the study's public registry record.
Research Nurse Navigator · (212) 342 5162 · cancerclinicaltrials@cumc.columbia.edu
Seda Tolu, MD · 212-305-8923 · st3406@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07283822